The efficacy of above-label doses of long-acting somatostatin analogues for the management of patients with gastroenteropancreatic tumors

#3203

Introduction: Above-label doses of long-acting somatostatin analogues (SSAs) are increasingly used for the control of secretory syndrome or as anti-proliferative treatment in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Aim(s): The aim of this study was to evaluate the anti-proliferative effect of increased dose of SSAs in patients with GEP-NETs.

Materials and methods: We collected retrospectively the data of patients with GEP-NETs that received SSAs every 3 or 2 weeks, after disease progression on standard 4-weekly doses. We analysed clinical, biochemical and radiographic response data and identified factors that may influence the outcome.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Tsoli M, Daskalakis K, Koumarianou A, Kolomodi D, Anagnostou E,

Keywords: neuroendocrine tumor, somatostatin analogues, medical treatment,